Literature DB >> 23892612

The in ovo CAM-assay as a xenograft model for sarcoma.

Gwen M L Sys1, Lore Lapeire, Nikita Stevens, Herman Favoreel, Ramses Forsyth, Marc Bracke, Olivier De Wever.   

Abstract

Sarcoma is a very rare disease that is heterogeneous in nature, all hampering the development of new therapies. Sarcoma patients are ideal candidates for personalized medicine after stratification, explaining the current interest in developing a reproducible and low-cost xenotransplant model for this disease. The chick chorioallantoic membrane is a natural immunodeficient host capable of sustaining grafted tissues and cells without species-specific restrictions. In addition, it is easily accessed, manipulated and imaged using optical and fluorescence stereomicroscopy. Histology further allows detailed analysis of heterotypic cellular interactions. This protocol describes in detail the in ovo grafting of the chorioallantoic membrane with fresh sarcoma-derived tumor tissues, their single cell suspensions, and permanent and transient fluorescently labeled established sarcoma cell lines (Saos-2 and SW1353). The chick survival rates are up to 75%. The model is used to study graft- (viability, Ki67 proliferation index, necrosis, infiltration) and host (fibroblast infiltration, vascular ingrowth) behavior. For localized grafting of single cell suspensions, ECM gel provides significant advantages over inert containment materials. The Ki67 proliferation index is related to the distance of the cells from the surface of the CAM and the duration of application on the CAM, the latter determining a time frame for the addition of therapeutic products.

Entities:  

Mesh:

Year:  2013        PMID: 23892612      PMCID: PMC3845689          DOI: 10.3791/50522

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  27 in total

1.  Vascularization of normal and neoplastic tissues grafted to the chick chorioallantois. Role of host and preexisting graft blood vessels.

Authors:  D H Ausprunk; D R Knighton; J Folkman
Journal:  Am J Pathol       Date:  1975-06       Impact factor: 4.307

2.  Transepithelial invasion and intramesenchymal infiltration of the chick embryo chorioallantois by tumor cell lines.

Authors:  P B Armstrong; J P Quigley; E Sidebottom
Journal:  Cancer Res       Date:  1982-05       Impact factor: 12.701

3.  Accessing key steps of human tumor progression in vivo by using an avian embryo model.

Authors:  Martin Hagedorn; Sophie Javerzat; Delphine Gilges; Aurélie Meyre; Benjamin de Lafarge; Anne Eichmann; Andreas Bikfalvi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-21       Impact factor: 11.205

Review 4.  Patient-derived tumour xenografts as models for oncology drug development.

Authors:  John J Tentler; Aik Choon Tan; Colin D Weekes; Antonio Jimeno; Stephen Leong; Todd M Pitts; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2012-04-17       Impact factor: 66.675

5.  Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors.

Authors:  Valentina Vaira; Giuseppe Fedele; Saumyadipta Pyne; Ester Fasoli; Giorgia Zadra; Dyane Bailey; Eric Snyder; Alice Faversani; Guido Coggi; Richard Flavin; Silvano Bosari; Massimo Loda
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

6.  Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas.

Authors:  J Hoffmann; P Schmidt-Peter; W Hänsch; H Naundorf; A Bunge; M Becker; I Fichtner
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

Review 7.  The chick embryo and its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systems.

Authors:  Angelica Vargas; Magali Zeisser-Labouèbe; Norbert Lange; Robert Gurny; Florence Delie
Journal:  Adv Drug Deliv Rev       Date:  2007-08-16       Impact factor: 15.470

8.  Tumor grafts derived from sarcoma patients retain tumor morphology, viability, and invasion potential and indicate disease outcomes in the chick chorioallantoic membrane model.

Authors:  Gwen Sys; Mieke Van Bockstal; Ramses Forsyth; Maurice Balke; Bart Poffyn; Dirk Uyttendaele; Marc Bracke; Olivier De Wever
Journal:  Cancer Lett       Date:  2012-07-24       Impact factor: 8.679

Review 9.  Sarcoma.

Authors:  Keith M Skubitz; David R D'Adamo
Journal:  Mayo Clin Proc       Date:  2007-11       Impact factor: 7.616

10.  Chick chorioallantoic membrane (CAM) assay as an in vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis.

Authors:  Noor A Lokman; Alison S F Elder; Carmela Ricciardelli; Martin K Oehler
Journal:  Int J Mol Sci       Date:  2012-08-10       Impact factor: 6.208

View more
  26 in total

Review 1.  The chick chorioallantoic membrane (CAM) as a versatile patient-derived xenograft (PDX) platform for precision medicine and preclinical research.

Authors:  Logan C DeBord; Ravi R Pathak; Mariana Villaneuva; Hsuan-Chen Liu; Daniel A Harrington; Wendong Yu; Michael T Lewis; Andrew G Sikora
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

2.  The In Ovo Chick Chorioallantoic Membrane (CAM) Assay as an Efficient Xenograft Model of Hepatocellular Carcinoma.

Authors:  Michael Li; Ravi R Pathak; Esther Lopez-Rivera; Scott L Friedman; Julio A Aguirre-Ghiso; Andrew G Sikora
Journal:  J Vis Exp       Date:  2015-10-09       Impact factor: 1.355

3.  Chick Heart Invasion Assay for Testing the Invasiveness of Cancer Cells and the Activity of Potentially Anti-invasive Compounds.

Authors:  Marc E Bracke; Bart I Roman; Christian V Stevens; Liselot M Mus; Virinder S Parmar; Olivier De Wever; Marc M Mareel
Journal:  J Vis Exp       Date:  2015-06-06       Impact factor: 1.355

4.  Quinazoline clubbed 1,3,5-triazine derivatives as VEGFR2 kinase inhibitors: design, synthesis, docking, in vitro cytotoxicity and in ovo antiangiogenic activity.

Authors:  Prateek Pathak; Parjanya Kumar Shukla; Vikas Kumar; Ankit Kumar; Amita Verma
Journal:  Inflammopharmacology       Date:  2018-04-16       Impact factor: 4.473

Review 5.  The chicken chorioallantoic membrane model in biology, medicine and bioengineering.

Authors:  Patrycja Nowak-Sliwinska; Tatiana Segura; M Luisa Iruela-Arispe
Journal:  Angiogenesis       Date:  2014-08-20       Impact factor: 9.596

6.  HRAS-driven cancer cells are vulnerable to TRPML1 inhibition.

Authors:  Jewon Jung; Kwang-Jin Cho; Ali K Naji; Kristen N Clemons; Ching On Wong; Mariana Villanueva; Steven Gregory; Nicholas E Karagas; Lingxiao Tan; Hong Liang; Morgan A Rousseau; Kelly M Tomasevich; Andrew G Sikora; Ilya Levental; Dharini van der Hoeven; Yong Zhou; John F Hancock; Kartik Venkatachalam
Journal:  EMBO Rep       Date:  2019-02-20       Impact factor: 8.807

7.  Optimized ex-ovo culturing of chick embryos to advanced stages of development.

Authors:  Kellie Cloney; Tamara Anne Franz-Odendaal
Journal:  J Vis Exp       Date:  2015-01-24       Impact factor: 1.355

8.  Oncogenic role of SFRP2 in p53-mutant osteosarcoma development via autocrine and paracrine mechanism.

Authors:  Huensuk Kim; Seungyeul Yoo; Ruoji Zhou; An Xu; Jeffrey M Bernitz; Ye Yuan; Andreia M Gomes; Michael G Daniel; Jie Su; Elizabeth G Demicco; Jun Zhu; Kateri A Moore; Dung-Fang Lee; Ihor R Lemischka; Christoph Schaniel
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-01       Impact factor: 11.205

9.  Ethanol extract of Lophatheri Herba exhibits anti-cancer activity in human cancer cells by suppression of metastatic and angiogenic potential.

Authors:  Aeyung Kim; Minju Im; Min Jung Gu; Jin Yeul Ma
Journal:  Sci Rep       Date:  2016-11-03       Impact factor: 4.379

10.  Non-invasive imaging of engineered human tumors in the living chicken embryo.

Authors:  Benedict Jefferies; Florian Lenze; Anuja Sathe; Nguyen Truong; Martina Anton; Rüdiger von Eisenhart-Rothe; Roman Nawroth; Philipp Mayer-Kuckuk
Journal:  Sci Rep       Date:  2017-07-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.